“Splunk Inc. first in delivering “aha” moments from machine data, today announced biotechnology company Recursion Pharmaceuticals is using Splunk® Enterprise and the Splunk Machine Learning Toolkit to reach its goal of treating 100 molecular genetic diseases by 2025. With Splunk, Recursion has combined biological science with machine learning to generate and analyze data from tens of thousands of images of cell cultures and trillions of DNA strands. Watch the Recursion Pharmaceuticals video and learn more about how Recursion is using Splunk to converge science, research and automation to meet the 2025 goal.”
“Recursion’s legacy management strategy could not keep pace with the large amounts of time-series data that was produced from an increasing number of computer-controlled instruments capturing more than 700,000 TIFF files per week. After evaluating open source alternatives, Recursion used Splunk Enterprise to streamline information gathering and optimize its laboratory procedures. Splunk Enterprise helped scientists realize value in just three days, providing answers to Recursion across a variety of data types…” Read the full news release here.
Source: Splunk Machine Learning Helps Recursion Pharmaceuticals Treat Genetic Diseases, November 7, 2017. Splunk.
